Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acsami.1c08174 http://scihub22266oqcxt.onion/10.1021/acsami.1c08174 34379400!ä!34379400 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34379400&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       ACS+Appl+Mater+Interfaces 2021 ; 13 (33): 38990-39002 Nephropedia Template TP {{tp|p=34379400|t=2021. Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Proteins |pdf=|usr=}}{{34379400}} gab.com Text Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Proteins JO: ACS Appl Mater Interfaces http://www.kidney.de/pget.php?&tw=1&pmid=34379400 #FOAvip The ongoing COVID-19 pandemic has clearly established how vital rapid, widely accessible diagnostic tests are in controlling infectious diseases and how difficult and slow it is to scale existing technologies. Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks. The pair with the highest biomarker sensitivity was then integrated into a 10 min, vertical-flow cellulose paper test. Notably, the as-identified affinity proteins were compatible with a roll-to-roll printing process for large-scale manufacturing of tests. The test achieved 40 and 80 pM limits of detection in 1x phosphate-buffered saline (mock swab) and saliva matrices spiked with cell-culture-generated SARS-CoV-2 viruses and is also capable of detection of N-protein from characterized clinical swab samples. Hence, this work paves the way toward the mass production of cellulose paper-based assays which can address the shortages faced due to dependence on nitrocellulose and current manufacturing techniques. Further, the results reported herein indicate the promise of RAPIDS and engineered binder proteins for the timely and flexible development of clinically relevant diagnostic tests in response to emerging infectious diseases. Twit Text FOAVip Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Proteins ????ACS Appl Mater Interfaces http://www.kidney.de/pget.php?&tw=1&pmid=34379400 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34379400 #FOAvip English Wikipedia <ref>{{Cite pmid|34379400}}</ref> Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Proteins #MMPMID34379400 Kim S; Yee E; Miller EA; Hao Y; Tay DMY; Sung KJ; Jia H; Johnson JM; Saeed M; Mace CR; Yuksel Yurt D; Sikes HD ACS Appl Mater Interfaces 2021[Aug]; 13 (33): 38990-39002 PMID34379400show ga The ongoing COVID-19 pandemic has clearly established how vital rapid, widely accessible diagnostic tests are in controlling infectious diseases and how difficult and slow it is to scale existing technologies. Here, we demonstrate the use of the rapid affinity pair identification via directed selection (RAPIDS) method to discover multiple affinity pairs for SARS-CoV-2 nucleocapsid protein (N-protein), a biomarker of COVID-19, from in vitro libraries in 10 weeks. The pair with the highest biomarker sensitivity was then integrated into a 10 min, vertical-flow cellulose paper test. Notably, the as-identified affinity proteins were compatible with a roll-to-roll printing process for large-scale manufacturing of tests. The test achieved 40 and 80 pM limits of detection in 1x phosphate-buffered saline (mock swab) and saliva matrices spiked with cell-culture-generated SARS-CoV-2 viruses and is also capable of detection of N-protein from characterized clinical swab samples. Hence, this work paves the way toward the mass production of cellulose paper-based assays which can address the shortages faced due to dependence on nitrocellulose and current manufacturing techniques. Further, the results reported herein indicate the promise of RAPIDS and engineered binder proteins for the timely and flexible development of clinically relevant diagnostic tests in response to emerging infectious diseases. |Antigens, Viral/*analysis[MESH] |Biomarkers/analysis[MESH] |Biosensing Techniques[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/prevention & control[MESH] |Cellulose/chemistry[MESH] |Enzyme-Linked Immunosorbent Assay/methods[MESH] |Fluorescent Dyes/chemistry[MESH] |Humans[MESH] |Microfluidic Analytical Techniques/methods[MESH] |Nucleocapsid Proteins/*analysis[MESH] |Peptide Library[MESH] |Protein Binding[MESH]Developing a SARS-CoV-2 Antigen Test Using Engineered Affinity Protein(epmc).pdf DeepDyve Pubget Overpricing